Impact of adverse events on ventricular assist device outcomes

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 89-100

  Adzic, Aleksandar ^a   Patel, Snehal R ^a   Maybaum, Simon ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Aortic insufficiency; Continuous flow; Device malfunction; Gastrointestinal bleeding; Infection; Left ventricular assist device(s); Pump thrombosis; Stroke

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; OCTREOTIDE; THROMBIN INHIBITOR;

ADVERSE OUTCOME; ANTIBIOTIC PROPHYLAXIS; ANTICOAGULANT THERAPY; AORTA VALVE REGURGITATION; ARTICLE; BLOODSTREAM INFECTION; CEREBROVASCULAR ACCIDENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DEVICE INFECTION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; IATROGENIC DISEASE; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DEVICE COMPLICATION; MEDICAL DEVICE MALFUNCTION; MYCOSIS; OUTCOME ASSESSMENT; PUMP THROMBOSIS; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; VENTRICULAR ASSIST DEVICE;

EID: 84873710120     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0127-3     Document Type: Article

References (114)

1. • Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54(4):312-21. HeartMate II bridge to transplant approval trial: the 281 subjects include the study and early continued access protocol.
2. • John R, Naka Y, Smedira NG, et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg. 2011;92(4):1406-13. Comparison of 486 HMII bridge to transplant study and continued access protocol subjects, versus the first 1,496 subjects enrolled into INTERMACS.
3. • Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241-51. The HMII destination therapy approval trial.
4. • Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241-8. Comparison of the HMII destination therapy study subjects versus the initial 281 subjects in the continued access protocol.
5. • Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125(25):3191-200. The HeartWare bridge to transplant approval trial.
6. INTERMACS Appendix A-Adverse Event Definitions. Version 3.0. Available at Accessed October 2012.
7. FDA Executive Summary Prepared for the April 25, 2012 meeting of the Circulatory System Devices Panel P100047 HeartWare Ventricular Assist System HeartWare, Inc. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/ CirculatorySystemDevicesPanel/UCM301222.pdf 2012.
8. Agarwal R, Adatya S, Uriel N, Jorde UP. Clinical impact, diagnosis, and management of a disconnected outflow graft bend relief in a patient supported by the HeartMate II left ventricular assist system. J Heart Lung Transplant. 2012;31(11):1238-9.
9. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation. 2012;125(24):3038-47.
10. Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant. 2009;28(9):881-7.
11. Pereira NL, Chen D, Kushwaha SS, Park SJ. Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. Interact Cardiovasc Thorac Surg. 2010;11(4):503-5.
12. Catena E, Milazzo F, Montorsi E, et al. Left ventricular support by axial flow pump: the echocardiographic approach to device malfunction. J Am Soc Echocardiogr. 2005;18(12):1422.
13. Paluszkiewicz L, Gursoy D, Spiliopoulos S, et al. HeartMate II ventricular assist device thrombosis-an echocardiographic approach to diagnosis: can Doppler evaluation of flow be useful? J Am Soc Echocardiogr. 2011;24(3):350 e1-4.
14. Paluszkiewicz L, Schulte-Eistrup S, Kortke H, Morshuis M, Gummert J. Thrombosis of the LVAD inflow cannula detected by transthoracic echocardiography: 2D and 3D thrombus visualization. Echocardiography. 2011;28(9):E194-5.
15. Miyake Y, Sugioka K, Bussey CD, Di Tullio M, Homma S. Left ventricular mobile thrombus associated with ventricular assist device: diagnosis by transesophageal echocardiography. Circ J. 2004;68(4):383-4.
16. Mishkin JD, Enriquez JR, Meyer DM, et al. Utilization of cardiac computed tomography angiography for the diagnosis of left ventricular assist device thrombosis. Circ Heart Fail. 2012;5(2):e27-9.
17. •• Slaughter MS, Pagani FD, Rogers JG, et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant. 2010;29(4 Suppl):S1-S39. White paper on the clinical management of axial flow LVADs.
18. • Uriel N, Morrison KA, Garan AR, et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the columbia ramp study. J Am Coll Cardiol. 2012;60(18):1764-75. Novel report of the use of echocardiography during ramp speed increases for the diagnosis of pump thrombus.
19. Al-Quthami AH, Jumean M, Kociol R, et al. Eptifibatide for the treatment of HeartMate II left ventricular assist device thrombosis. Circ Heart Fail. 2012;5(4):e68-70.
20. Thomas MD, Wood C, Lovett M, Dembo L, O'Driscoll G. Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban. J Heart Lung Transplant. 2008;27(8):925-7.
21. Meyer AL, Kuehn C, Weidemann J, et al. Thrombus formation in a HeartMate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008;135(1):203-4.
22. Rothenburger M, Wilhelm MJ, Hammel D, et al. Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator. Circulation. 2002;106(12 Suppl 1):I189-92.
23. Ninios V, Visouli A, Pitsis A. Images in cardiovascular medicine. Repeated successful thrombolysis of a Jarvik 2000 left ventricular assist device in a patient with noncompaction cardiomyopathy. Circulation. 2010;121(3):e13-4.
24. Kiernan MS, Pham DT, DeNofrio D, Kapur NK. Management of HeartWare left ventricular assist device thrombosis using intracavitary thrombolytics. J Thorac Cardiovasc Surg. 2011;142(3):712-4.
25. Kamouh A, John R, Eckman P. Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics. Ann Thorac Surg. 2012;94(1):281-3.
26. NIH Stroke Scale: National Institute of Neurological Disorders and Stroke. Available at http://www.ninds.nih.gov/doctors/NIH-Stroke-Scale.pdf.; Accessed October 2012.
27. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-7.
28. Baldwin JT, Mann DL. NHLBI's program for VAD therapy for moderately advanced heart failure: the REVIVE-IT pilot trial. J Card Fail. 2010;16(11):855-8.
29. Saeed O, Patel J, Nucci C, et al. 771 Non Invasive Blood Pressure (BP) Measurement with the Terumo Elemano™ Is More Reliable during Return of Pulsatile Flow in Patients on Continuous Flow (CF) LVAD Support. J Heart Lung Transplant. 2012;31(4, Supplement):S263.
30. Rao KK, Haro GJ, Ayers CR, et al. 579 Blood Pressure Measurement in Patients with Continuous Flow LVADs: comparing the Doppler Sphygmomanometer, the Nexfin Device, and the Arterial Line. J Heart Lung Transplant. 2012;31(4, Supplement):S200-1.
31. Schulze PC, Bartels MN, Chung CJ, et al. 559 Increased Blood Pressure Variability in Patients Supported by Continuous Flow Left Ventricular Assist Devices: a Novel Vascular Phenotype in the Absence of Pulsatility? J Heart Lung Transplant. 2012;31(4, Supplement):S194.
32. Aggarwal A, Gupta A, Kumar S, et al. Are blood stream infections associated with an increased risk of hemorrhagic stroke in patients with a left ventricular assist device? ASAIO J. 2012;58(5):509-13.
33. Poston RS, Husain S, Sorce D, et al. LVAD bloodstream infections: therapeutic rationale for transplantation after LVAD infection. J Heart Lung Transplant. 2003;22(8):914-21.
34. Toda K, Yonemoto Y, Fujita T, et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann Thorac Surg. 2012;94(5):1387-93.
35. Hannan MM, Husain S, Mattner F, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant. 2011;30(4):375-84.
36. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29(1):1-10.
37. Holman WL, Pae WE, Teutenberg JJ, et al. INTERMACS: interval analysis of registry data. J Am Coll Surg. 2009;208(5):755-61. discussion 61-2.
38. Nurozler F, Argenziano M, Oz MC, Naka Y. Fungal left ventricular assist device endocarditis. Ann Thorac Surg. 2001;71(2):614-8.
39. Shoham S, Shaffer R, Sweet L, et al. Candidemia in patients with ventricular assist devices. Clin Infect Dis. 2007;44(2):e9-e12.
40. Bagdasarian NG, Malani AN, Pagani FD, Malani PN. Fungemia associated with left ventricular assist device support. J Card Surg. 2009;24(6):763-5.
41. Monkowski DH, Axelrod P, Fekete T, et al. Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation. Transpl Infect Dis. 2007;9(2):114-20.
42. Simon D, Fischer S, Grossman A, et al. Left ventricular assist device-related infection: treatment and outcome. Clin Infect Dis. 2005;40(8):1108-15.
43. Raymond AL, Kfoury AG, Bishop CJ, et al. Obesity and left ventricular assist device driveline exit site infection. ASAIO J. 2010;56(1):57-60.
44. Malani PN, Dyke DB, Pagani FD, Chenoweth CE. Nosocomial infections in left ventricular assist device recipients. Clin Infect Dis. 2002;34(10):1295- 300.
45. Dang NC, Topkara VK, Kim BT, et al. Nutritional status in patients on left ventricular assist device support. J Thorac Cardiovasc Surg. 2005;130(5):e3-4.
46. • Goldstein DJ, Naftel D, Holman W, et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant. 2012;31(11):1151-7. INTERMACS analysis of 2006 CF LVAD patients: description of incidence, risk factors, and outcomes of percutaneous site infections.
47. Holman WL. Microbiology of infection in mechanical circulatory support. Int J Artif Organs. 2007;30(9):764-70.
48. Padera RF. Infection in ventricular assist devices: the role of biofilm. Cardiovasc Pathol. 2006;15(5):264-70.
49. Walker PC, DePestel DD, Miles NA, Malani PN. Surgical infection prophylaxis for left ventricular assist device implantation. J Card Surg. 2011;26(4):440-3.
50. Pamboukian SV, Tallaj JA, Brown RN, et al. Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol. J Heart Lung Transplant. 2011;30(8):879-87.
51. Mehta SM, Pae Jr WE, Rosenberg G, et al. The LionHeart LVD-2000: a completely implanted left ventricular assist device for chronic circulatory support. Ann Thorac Surg. 2001;71(3 Suppl):S156-61. discussion S83-4.
52. Pae WE, Connell JM, Adelowo A, et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant. 2007;26(3):219-29.
53. Fischer SA, Trenholme GM, Costanzo MR, Piccione W. Infectious complications in left ventricular assist device recipients. Clin Infect Dis. 1997;24(1):18-23.
54. • Maniar S, Kondareddy S, Topkara VK. Left ventricular assist device-related infections: past, present and future. Expert Rev Med Devices. 2011;8(5):627-34. Comprehensive recent review of LVAD infections.
55. •• Califano S, Pagani FD, Malani PN. Left ventricular assist device-associated infections. Infect Dis Clin North Am. 2012;26(1):77-87. Comprehensive recent review of LVAD infections.
56. Vilchez RA, McEllistrem MC, Harrison LH, et al. Relapsing bacteremia in patients with ventricular assist device: an emergent complication of extended circulatory support. Ann Thorac Surg. 2001;72(1):96-101.
57. Prendergast TW, Todd BA, Beyer 3rd AJ, et al. Management of left ventricular assist device infection with heart transplantation. Ann Thorac Surg. 1997;64(1):142-7.
58. Schulman AR, Martens TP, Christos PJ, et al. Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2007;133(3):841-2.
59. Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg. 2010;90(4):1270-7.
60. Sinha P, Chen JM, Flannery M, et al. Infections during left ventricular assist device support do not affect posttransplant outcomes. Circulation. 2000;102(19 Suppl 3):III194-9.
61. Chinn R, Dembitsky W, Eaton L, et al. Multicenter experience: prevention and management of left ventricular assist device infections. ASAIO J. 2005;51(4):461-70.
62. Baradarian S, Stahovich M, Krause S, Adamson R, Dembitsky W. Case series: clinical management of persistent mechanical assist device driveline drainage using vacuum-assisted closure therapy. ASAIO J. 2006;52(3):354-6.
63. Pasque MK, Hanselman T, Shelton K, et al. Surgical management of Novacor drive-line exit site infections. Ann Thorac Surg. 2002;74(4):1267-8.
64. de Jonge KC, Laube HR, Dohmen PM, Ivancevic V, Konertz WF. Diagnosis and management of left ventricular assist device valve-endocarditis: LVAD valve replacement. Ann Thorac Surg. 2000;70(4):1404-5.
65. Litzler PY, Manrique A, Etienne M, et al. Leukocyte SPECT/CT for detecting infection of left-ventricular-assist devices: preliminary results. J Nucl Med. 2010;51(7):1044-8.
66. Tjan TD, Asfour B, Hammel D, et al. Wound complications after left ventricular assist device implantation. Ann Thorac Surg. 2000;70(2):538-41.
67. Yuh DD, Albaugh M, Ullrich S, Conte JV. Treatment of ventricular assist device driveline infection with vacuum-assisted closure system. Ann Thorac Surg. 2005;80(4):1493-5.
68. Garatti A, Giuseppe B, Russo CF, Marco O, Ettore V. Drive-line exit-site infection in a patient with axial-flow pump support: successful management using vacuum-assisted therapy. J Heart Lung Transplant. 2007;26(9):956-9.
69. McKellar SH, Allred BD, Marks JD, et al. Treatment of infected left ventricular assist device using antibiotic-impregnated beads. Ann Thorac Surg. 1999;67(2):554-5.
70. Holman WL, Fix RJ, Foley BA, et al. Management of wound and left ventricular assist device pocket infection. Ann Thorac Surg. 1999;68(3):1080-2.
71. Hutchinson OZ, Oz MC, Ascherman JA. The use of muscle flaps to treat left ventricular assist device infections. Plast Reconstr Surg. 2001;107(2):364-73.
72. •• Suarez J, Patel CB, Felker GM, et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail. 2011;4(6):779-84. Recent comprehensive review of gastrointestinal bleeding in CF LVAD patients.
73. John R, Kamdar F, Eckman P, et al. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. Ann Thorac Surg. 2011;92(5):1593-9. discussion 9-600.
74. Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2011;30(8):849-53.
75. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137(1):208-15.
76. Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31(7):715-8.
77. Patel SR, Rivera A, Patel J, et al. 74 Gastrointestinal Bleeding Is Not Associated with Pump Speed and Aortic Valve Opening in Patients Supported with the HeartMate II LVAD. J Heart Lung Transplant. 2012;31(4, Supplement):S34.
78. • Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol. 2010;56(15):1207-13. First large report of acquired von Willebrand deficiency in HMII recipients.
79. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635-41.
80. Aggarwal A, Pant R, Kumar S, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg. 2012;93(5):1534-40.
81. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med. 1988;84(4):683-90.
82. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail. 2010;3(6):675-81.
83. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg. 2010;90(4):1263-9.
84. Strueber M, Malehsa D, Avsar M, et al. 453 Gastrointestinal Bleeding after Implantation of the HeartWare HVAD Left Ventricular Assist Device. J Heart Lung Transplant. 2011;30(4, Supplement):S154.
85. Coutance G, Repesse Y, Belin A, Massetti M. Acquired von Willebrand disease in Jarvik 2000 recipients: a single center experience. Int J Cardiol. 2012;159(1):57-8.
86. Heyde E. Gastrointestinal Bleeding in Aortic Stenosis. N Engl J Med. 1958;259(4):196.
87. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link? Lancet. 1992;340(8810):35-7.
88. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343-9.
89. Veyradier A, Balian A, Wolf M, et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology. 2001;120(2):346-53.
90. Boley SJ, Sammartano R, Adams A, et al. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. Gastroenterology. 1977;72(4 Pt 1):650-60.
91. Cappell MS, Lebwohl O. Cessation of recurrent bleeding from gastrointestinal angiodysplasias after aortic valve replacement. Ann Intern Med. 1986;105(1):54-7.
92. Kushnir VM, Sharma S, Ewald GA, et al. Evaluation of GI bleeding after implantation of left ventricular assist device. Gastrointest Endosc. 2012;75(5):973-9.
93. Sarosiek K, Bogar L, Hirose H, et al. 543 An Old Problem with a New Therapy: GI Bleeding in VAD Patients and Deep Bowel Enteroscopy (Double Balloon/Spiral Enteroscopy). J Heart Lung Transplant. 2012;31(4, Supplement):S188.
94. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg. 2008;33(4):679-84.
95. Toda K, Fujita T, Domae K, et al. Late aortic insufficiency related to poor prognosis during left ventricular assist device support. Ann Thorac Surg. 2011;92(3):929-34.
96. Pak SW, Uriel N, Takayama H, et al. Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant. 2010;29(10):1172-6.
97. Cowger J, Pagani FD, Haft JW, et al. The development of aortic insufficiency in left ventricular assist device-supported patients. Circ Heart Fail. 2010;3(6):668-74.
98. Soleimani B, Haouzi A, Manoskey A, et al. Development of aortic insufficiency in patients supported with continuous flow left ventricular assist devices. ASAIO J. 2012;58(4):326-9.
99. • Mudd JO, Cuda JD, Halushka M, et al. Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. J Heart Lung Transplant. 2008;27(12):1269-74. First series (9 patients) reporting aortic valve pathology during HMII support.
100. Samuels LE, Thomas MP, Holmes EC, et al. Insufficiency of the native aortic valve and left ventricular assist system inflow valve after support with an implantable left ventricular assist system: signs, symptoms, and concerns. J Thorac Cardiovasc Surg. 2001;122(2):380-1.
101. Balachandran K, Sucosky P, Jo H, Yoganathan AP. Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. Am J Physiol Heart Circ Physiol. 2009;296(3):H756-64.
102. May-Newman K, Hillen B, Dembitsky W. Effect of left ventricular assist device outflow conduit anastomosis location on flow patterns in the native aorta. ASAIO J. 2006;52(2):132-9.
103. Murthy S, Bello R, Casazza D, Maybaum S, Goldstein D. 766 Echocardiographic and Pathological Correlates of Aortic Regurgitation in Continuous-Flow LVAD Support. J Heart Lung Transplant. 2012;31(4, Supplement):S261.
104. •• John R, Mantz K, Eckman P, Rose A, May-Newman K. Aortic valve pathophysiology during left ventricular assist device support. J Heart Lung Transplant. 2010;29(12):1321-9. Comprehensive review of aortic valve disease during CF LVAD support.
105. Saeed O, Patel J, Rivera A, et al. Abstract 11343: Aortic Valve Opening Predicts Thrombotic Events during Continous Flow Left Ventricular Assist Device (CF-LVAD) Support. Circulation. 2012;126(A11343).
106. Morgan JA, Brewer RJ, Nemeh HW, et al. Management of aortic valve insufficiency in patients supported by long-term continuous flow left ventricular assist devices. Ann Thorac Surg. 2012;94(5):1710-2.
107. Feldman CM, Silver MA, Sobieski MA, Slaughter MS. Management of aortic insufficiency with continuous flow left ventricular assist devices: bioprosthetic valve replacement. J Heart Lung Transplant. 2006;25(12):1410-2.
108. Russo MJ, Freed BH, Jeevanandam V, et al. Percutaneous transcatheter closure of the aortic valve to treat cardiogenic shock in a left ventricular assist device patient with severe aortic insufficiency. Ann Thorac Surg. 2012;94(3):985-8.
109. Freed BH, Paul JD, Bhave NM, et al. Percutaneous transcatheter closure of the native aortic valve to treat de novo aortic insufficiency after implantation of a left ventricular assist device. JACC Cardiovasc Interv. 2012;5(3):358-9.
110. Grohmann J, Blanke P, Benk C, Schlensak C. Trans-catheter closure of the native aortic valve with an Amplatzer Occluder to treat progressive aortic regurgitation after implantation of a left-ventricular assist device. Eur J Cardiothorac Surg. 2011;39(6):e181-3.
111. D'Ancona G, Pasic M, Buz S, et al. TAVI for pure aortic valve insufficiency in a patient with a left ventricular assist device. Ann Thorac Surg. 2012;93(4):e89-91.
112. Santini F, Forni A, Dandale R, et al. First successful management of aortic valve insufficiency associated with HeartMate II left ventricular assist device support by transfemoral CoreValve implantation: the Columbus's egg? JACC Cardiovasc Interv. 2012;5(1):114-5.
113. Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park's stitch). J Thorac Cardiovasc Surg. 2004;127(1):264-6.
114. Goda A, Takayama H, Pak SW, et al. Aortic valve procedures at the time of ventricular assist device placement. Ann Thorac Surg. 2011;91(3):750-4.